Yili Chuanning Bio(301301.SZ)

Company Encyclopedia
View More
name
Yili Chuanning Bio
301301.SZ
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ekdoin, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop planting, inspection, technical advisory, and asset investment activities.
1.522 T
301301.SZMarket value -Rank by Market Cap -/-

Financial Score

01/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking25/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.08%B
    • Profit Margin19.75%A
    • Gross Margin28.64%C
  • Growth ScoreD
    • Revenue YoY-16.85%E
    • Net Profit YoY-32.01%D
    • Total Assets YoY-2.09%D
    • Net Assets YoY4.77%B
  • Cash ScoreD
    • Cash Flow Margin506.31%C
    • OCF YoY-16.85%E
  • Operating ScoreC
    • Turnover0.45C
  • Debt ScoreA
    • Gearing Ratio23.03%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Weight-Loss Drug Prices Drop in China as Patent Expiry Nears

    Prices of weight-loss drugs in China, including Wegovy and Mounjaro, are dropping as patent expirations approach. Wegovy's price has halved to CNY987.48 from CNY1,893.67, while Mounjaro's presale price is now as low as CNY450, down from CNY2,180. Novo Nordisk's price cuts aim to enhance patient compliance. The patent for semaglutide (Wegovy) expires on March 20, prompting domestic firms to prepare generic versions. This price reduction is expected to impact the industry and future weight-loss drug pricing significantly.

    Yicai·
    Yicai·

    Yili Chuanning Bio: Net profit in the third quarter was 157 million yuan, a year-on-year decrease of 49.44%

    Yili Chuanning Bio announced that its revenue for the third quarter was 1.087 billion yuan, a year-on-year decrease of 13.76%; net profit was 157 million yuan, a year-on-year decrease of 49.44%. Revenue for the first three quarters was 3.436 billion yuan, a year-on-year decrease of 22.90%; net profit was 611 million yuan, a year-on-year decrease of 43.17%

    Zhitong·
    SZ
    301301
    0.00%
    Zhitong·
    SZ
    301301
    0.00%

    Yili Chuanning Bio has been approved to register 1 billion yuan medium-term notes

    According to the Zhitong Finance APP, Yili Chuanning Bio announced that the company has received the "Acceptance of Registration Notice" issued by the Association of Dealers. The Association of Dealers has agreed to accept the registration of the company's medium-term notes, with a registered amount of 1 billion yuan. The registration quota is valid for 2 years from the date of this notice

    Zhitong·
    SZ
    301301
    0.00%
    Zhitong·
    SZ
    301301
    0.00%

    KELUN PHARMA: With the arrival of the peak season in the fourth quarter, Yili Chuanning Bio's performance is expected to improve

    KELUN PHARMA stated in an institutional research that the demand for the antibiotic sector is stabilizing. Despite price fluctuations, the company has a clear cost advantage. Yili Chuanning Bio expects a significant decline in overall performance this year compared to last year, affected by the market price of penicillin. With the arrival of the peak season in the fourth quarter, performance is expected to improve, and the volume of synthetic biology products in 2026 and the rebound in penicillin prices will bring greater improvement potential

    Zhitong·
    SZ
    002422
    +1.80%
    SZ
    301301
    0.00%
    Zhitong·
    SZ
    002422
    +1.80%
    SZ
    301301
    0.00%

    Yili Chuanning Bio: In the first half of the year, the net profit attributable to the parent company was 455 million yuan, a year-on-year decrease of 40.64%

    On August 25th, Yili Chuanning Bio disclosed its semi-annual report, stating that the company achieved operating revenue of 2.349 billion yuan in the first half of the year, a year-on-year decrease of 26.50%; the net profit attributable to shareholders of the listed company was 455 million yuan, down from 766 million yuan in the same period last year, a year-on-year decrease of 40.64%; the basic earnings per share were 0.2 yuan

    Zhitong·
    SZ
    301301
    0.00%
    Zhitong·
    SZ
    301301
    0.00%
    © 2026 Longbridge｜Disclaimer